Neumora Therapeutics, Valuation
| NMRA Stock | 1.13 0.07 5.83% |
Today, the firm appears to be undervalued. Neumora Therapeutics, secures a last-minute Real Value of USD4.77 per share. The latest price of the firm is USD1.13. Our model forecasts the value of Neumora Therapeutics, from analyzing the firm fundamentals such as Shares Owned By Insiders of 27.52 %, return on equity of -0.64, and Current Valuation of (111.35 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Neumora Therapeutics,'s valuation include:
Undervalued
Today
Please note that Neumora Therapeutics,'s price fluctuation is dangerous at this time. Calculation of the real value of Neumora Therapeutics, is based on 3 months time horizon. Increasing Neumora Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neumora Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neumora Stock. However, Neumora Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.13 | Real 4.77 | Target 15.54 | Hype 1.11 | Naive 1.04 |
The real value of Neumora Stock, also known as its intrinsic value, is the underlying worth of Neumora Therapeutics, Company, which is reflected in its stock price. It is based on Neumora Therapeutics,'s financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Neumora Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Neumora Therapeutics, helps investors to forecast how Neumora stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neumora Therapeutics, more accurately as focusing exclusively on Neumora Therapeutics,'s fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Neumora Therapeutics,'s intrinsic value based on its ongoing forecasts of Neumora Therapeutics,'s financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Neumora Therapeutics,'s closest peers. If more than one evaluation category is relevant for Neumora Therapeutics, we suggest using both methods to arrive at a better estimate.
Neumora Therapeutics, Cash |
|
Neumora Valuation Trend
Comparing Neumora Therapeutics,'s enterprise value against its market capitalization is a good way to estimate the value of Neumora Therapeutics, uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Neumora Valuation Data Drivers
Neumora Therapeutics, Total Value Analysis
Neumora Therapeutics, is now projected to have valuation of (111.35 M) with market capitalization of 194.37 M, debt of 1.85 M, and cash on hands of . The negative valuation of Neumora Therapeutics, may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Neumora Therapeutics, fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(111.35 M) | 194.37 M | 1.85 M |
Neumora Therapeutics, Asset Utilization
One of the ways to look at asset utilization of Neumora is to check how much profit was generated for every dollar of assets it reports. Neumora Therapeutics, secures a negative usage of assets of -0.4 %, losing USD0.00405 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Neumora Therapeutics, shows how discouraging it operates for each dollar spent on its assets.Neumora Therapeutics, Ownership Allocation
Neumora Therapeutics, maintains a total of 161.98 Million outstanding shares. The majority of Neumora Therapeutics, outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neumora Therapeutics, to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neumora Therapeutics,. Please pay attention to any change in the institutional holdings of Neumora Therapeutics, as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Neumora Therapeutics, Profitability Analysis
Net Loss for the year was (243.79 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Neumora Therapeutics,'s worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Neumora Therapeutics, and how it compares across the competition.
About Neumora Therapeutics, Valuation
The stock valuation mechanism determines Neumora Therapeutics,'s current worth on a weekly basis. Our valuation model uses a comparative analysis of Neumora Therapeutics,. We calculate exposure to Neumora Therapeutics,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neumora Therapeutics,'s related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -768.2 K | -806.6 K |
Neumora Therapeutics, Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 159.4 M |
Neumora Therapeutics, Current Valuation Indicators
Valuation refers to the process of determining the present value of Neumora Therapeutics, and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Neumora we look at many different elements of the entity such as Neumora's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Neumora Therapeutics,, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Neumora Therapeutics,'s valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Neumora Therapeutics,'s worth.Complementary Tools for Neumora Stock analysis
When running Neumora Therapeutics,'s price analysis, check to measure Neumora Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neumora Therapeutics, is operating at the current time. Most of Neumora Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Neumora Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neumora Therapeutics,'s price. Additionally, you may evaluate how the addition of Neumora Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |